Navigation Links
ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/6/2011

IRVINE, Calif., Sept. 6, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) announced today that its Chief Executive Officer, Frank L. Jaksch, Jr., will be presenting the company's business strategy and growth opportunities at the 2011 Rodman & Renshaw Annual Global Investment Conference. The event will be held September 11-13, 2011 at the Waldorf Astoria in New York City.

ChromaDex is scheduled to make its presentation on Tuesday, September 13th at 11:30 a.m. local time. The company's presentation is currently available on its website, www.chromadex.com. For further details about the conference, please visit http://www.rodmanandrenshaw.com/conferences?id=162.

For more information about ChromaDex Corporation, visit www.chromadex.com and www.pteropure.com.

About ChromaDex®

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

ChromaDex Contact
Laura Carney
Administrative Assistant
949-419-0288
laurac@chromadex.com

ChromaDex Media Inquiries:
Chandler Chicco Agency
Kerry Sinclair, Media Specialist
310-309-1031
ksinclair@ccapr.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex Announces 2008 Year End Financial Results
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
5. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
6. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
7. InterMune to Present at Canaccord Adams Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
Breaking Biology News(10 mins):